A recent meta-analysis published in JAMA Internal Medicine (August 2023) found no evidence that the most common types of cancer screening are providing statistically significant benefits in overall survival, with the exception of colorectal cancer screening with sigmoidoscopy. How can this be?
Illumina Ventures today announced that Mara Aspinall, MBA, has joined the Company’s investment team as a Partner.
DELFI Diagnostics is developing a new generation of liquid biopsies that could advance these applications. Built on a new method called fragmentomics and amplified by machine learning, DELFI’s approach is already showing promise, providing early detection for lung, liver and other cancers, and could provide essential insights to inform precision medicine.
Illumina Ventures, a leading genomics and precision health venture firm, today announced plans to launch Illumina® Ventures Labs.
